Cadence Neuroscience

Executive Summary

Cadence Neuroscience is a Seattle-based medical device company founded in 2018, specializing in personalized, implantable neurostimulation systems for drug-resistant neurological disorders, with an initial focus on epilepsy. The company's technology, incubated at Mayo Clinic, combines proven hardware with novel adaptive software to deliver closed-loop neuromodulation tailored to individual patients. This approach aims to improve efficacy and reduce side effects compared to traditional open-loop devices, addressing a significant unmet need in epilepsy where approximately one-third of patients do not respond to medications. Cadence's platform is designed to be scalable to other conditions such as chronic pain, depression, and movement disorders, broadening its market potential. The company has made progress in refining its system through preclinical studies and early feasibility work, leveraging Mayo Clinic's clinical expertise and infrastructure. While still in the development stage, Cadence is positioned to enter first-in-human trials, which will be a critical proof-of-concept milestone. The global neuromodulation market is projected to exceed $10 billion by 2027, and epilepsy alone represents a multi-billion-dollar opportunity. With a strong IP portfolio, experienced leadership, and backing from a top-tier medical institution, Cadence Neuroscience has the potential to become a leader in adaptive neurostimulation. However, as a private company with no disclosed funding rounds or revenue, execution risk remains high, and clinical validation is essential before regulatory approval and commercial launch.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial initiation70% success
• Q4 2026FDA Breakthrough Device Designation80% success